Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$43.43 USD

43.43
889,958

+0.29 (0.67%)

Updated Mar 24, 2023 04:00 PM ET

After-Market: $43.45 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.52%
2Buy18.26%
3Hold9.60%
4Sell5.38%
5Strong Sell2.61%
S&P50010.68%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio

by Zacks Equity Research

Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.

CRISPR Therapeutics AG (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders

by Zacks Equity Research

Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.

Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA

by Zacks Equity Research

Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.

Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals

by Zacks Equity Research

CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals are part of the Zacks Industry Outlook article.

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $45.06, marking a +1.35% move from the previous day.

Here's Why You Should Add CRISPR Stock to Your Portfolio

by Zacks Equity Research

CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.

4 Biotech Stocks to Consider for Your Portfolio in 2023

by Zacks Equity Research

New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.

Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate

by Zacks Equity Research

Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.

Bellicum (BLCM) Down on Ending Development of CAR-T Candidates

by Zacks Equity Research

Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.

Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences

by Zacks Equity Research

Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.

Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges

by Zacks Equity Research

Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.

CRISPR Therapeutics AG (CRSP) Stock Moves -0.51%: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $44.92, moving -0.51% from the previous trading session.

Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why

by Zacks Equity Research

Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.

Novo Nordisk (NVO) Follows Lilly, to Cut Insulin Prices by 75%

by Zacks Equity Research

Novo Nordisk (NVO) plans to lower prices of several pre-filled insulin pens and vials by up to 75% in the United States. However, the company plans not to start this until January 2024.

AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?

by Zacks Equity Research

AstraZeneca (AZN) expects total revenues to increase in the low-to-mid single-digit percentage in 2023 at CER.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $45.15 in the latest trading session, marking a -1.25% move from the prior day.

Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals

by Zacks Equity Research

Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.

Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod

by Zacks Equity Research

Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.

Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret

by Zacks Equity Research

Zavzpret (zavegepant) is now part of Pfizer's (PFE) migraine drugs portfolio with the 2022 acquisition of Biohaven. Zavzpret provides migraine patients access to a fast-acting pain-relief option.

Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how BioLife Solutions, Inc. (BLFS) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.

Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.

Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate

by Zacks Equity Research

Trevena (TRVN) has initiated proof-of-concept study to evaluate TRV045 as a potential treatment for epilepsy and other CNS disorders.

BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies

by Zacks Equity Research

The FDA accepts BioMarin's (BMRN) label-expansion filing for Voxzogo to treat children under five years with achondroplasia. The agency extends the review period for Roctavian BLA.

Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review

by Zacks Equity Research

Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA